Female androgenetic alopecia, also called female pattern hair loss (FPHL), is caused by a combination of genetic predisposition, hormonal activity at the hair follicle, and age-related shifts in hormone balance. It affects roughly 40% of women by age 50. Unlike male pattern baldness, the role of androgens in FPHL is less straightforward, and some women develop it without any measurable hormone abnormality at all.
Genetics Play the Largest Role
Androgenetic alopecia is one of the most heritable skin-related traits. Twin and family studies estimate that genetics account for up to 80% of a person’s risk. But this isn’t a single-gene condition. It’s polygenic, meaning dozens or more genes each contribute a small amount of risk, and the specific combination you inherit determines whether and when thinning begins.
Importantly, the genes involved in female hair loss appear to differ partly from those in men. Researchers have tried to replicate the genetic markers linked to male pattern baldness in women and largely failed. The androgen receptor gene on the X chromosome, one of the strongest signals in men, shows only a weak association in women. More recent genome-wide studies have identified markers that reach significance exclusively in women, including variants in genes involved in cell signaling and communication between follicle cells. This means you can’t simply look at whether the men in your family are bald to predict your own risk. Maternal and paternal sides both contribute, and female-specific genetic pathways are still being mapped.
How Hormones Affect the Hair Follicle
In male pattern baldness, the mechanism is well established: testosterone is converted into a more potent form called DHT by an enzyme in the scalp, and DHT shrinks vulnerable follicles over time. Women have the same basic machinery, but several built-in protections slow this process down. Women’s scalp skin contains lower concentrations of androgen receptors and lower levels of the enzyme that converts testosterone to DHT. Perhaps most significantly, women’s frontal hair follicles contain six times more of an enzyme called aromatase than men’s. Aromatase converts androgens into estrogens locally at the follicle, essentially neutralizing them before they can do damage.
This is why female hair loss typically looks different from male hair loss. Rather than a receding hairline or bald spot, women tend to experience diffuse thinning along the crown and part line while the frontal hairline stays mostly intact. The aromatase in frontal follicles provides a protective buffer that men largely lack.
Still, some degree of androgen activity does appear to drive FPHL in many women. DHT binds to receptors inside hair follicle cells and activates genes that gradually transform thick, pigmented terminal hairs into fine, short, barely visible vellus hairs. This process, called follicular miniaturization, is identical under a microscope whether it’s happening in a man or a woman. Over successive hair cycles, the active growth phase shortens from its normal duration of several years down to just weeks or months, producing hairs that are thinner, shorter, and less visible with each round.
Why Menopause Is a Turning Point
Many women first notice thinning during or after menopause, and the timing is not coincidental. As ovarian function declines, estrogen and progesterone levels drop significantly. Meanwhile, androgen levels, though they also decrease with age, don’t fall as sharply. The result is a shift in the ratio of estrogens to androgens. Follicles that were previously protected by estrogen’s balancing effect become more exposed to the influence of testosterone and DHT.
Research comparing postmenopausal women with and without hair loss found that those with androgenetic alopecia had lower estrogen levels and higher levels of testosterone and DHT than their peers without thinning. This hormonal environment, rather than any single hormone being “too high,” creates the conditions for follicle miniaturization to accelerate. Women who were genetically predisposed but showed no visible thinning during their reproductive years may cross a threshold once that estrogen buffer diminishes.
The Connection to PCOS and Hyperandrogenism
In younger women, female pattern hair loss can be an early clinical sign of polycystic ovary syndrome (PCOS) or other conditions that raise androgen levels. PCOS is the most common endocrine disorder in women of reproductive age, and hair thinning on the scalp is recognized as one of its markers of excess androgen activity, alongside acne and excess body or facial hair. Not every woman with FPHL has PCOS, and not every woman with PCOS develops noticeable hair loss, but the overlap is significant enough that new or rapidly progressing thinning in a younger woman often prompts hormonal evaluation.
Other less common causes of elevated androgens, including adrenal gland disorders and certain ovarian tumors, can also trigger or worsen the same pattern of hair loss. When thinning appears suddenly, progresses quickly, or is accompanied by other signs of hormone imbalance like irregular periods or new facial hair growth, an underlying hormonal condition is more likely to be part of the picture.
Inflammation at the Follicle
Beyond genetics and hormones, low-grade inflammation around hair follicles contributes to the progression of androgenetic alopecia. Scalp biopsies from people with AGA show inflammatory cells clustered around the upper portion of affected follicles, with rings of scar-like collagen forming around them. This type of moderate to dense inflammation is found in AGA patients but is rare in people with healthy hair. The inflammation appears to compound the damage from hormonal miniaturization, and it may also reduce how well topical treatments work. Whether the inflammation is a cause, a consequence, or an accelerator of follicle shrinkage is still debated, but it clearly plays a role in how quickly thinning progresses.
Nutritional Factors That Worsen Thinning
Low iron stores and vitamin D deficiency don’t cause androgenetic alopecia on their own, but they can make it noticeably worse. Women with FPHL have significantly lower serum ferritin (the protein that stores iron) compared to women without hair loss. In one study, the average ferritin level in women with FPHL was about 24 micrograms per liter, compared to roughly 44 in controls, and lower levels correlated with more severe thinning. A ferritin cutoff of around 29 micrograms per liter distinguished women with FPHL from those without. For context, many labs list “normal” ferritin as anything above 12, which means your levels can be technically normal but still low enough to aggravate hair loss.
Vitamin D showed a similar pattern, with lower levels in women experiencing thinning. These deficiencies are common in women generally, especially those with heavy periods, plant-based diets, or limited sun exposure. Correcting them won’t reverse genetic hair loss, but it removes a factor that’s making it worse.
Why It Looks Different in Women Than in Men
The same underlying process, follicular miniaturization, drives hair loss in both sexes. But the pattern on the scalp differs because of the enzymatic and hormonal differences described above. Men typically lose hair in a predictable M-shaped recession at the temples and a widening bald spot at the crown. Women more commonly experience a gradual widening of the part line and diffuse thinning across the top of the scalp, while the frontal hairline is preserved. Complete baldness is rare in women.
This difference in presentation sometimes leads women to underestimate their hair loss or attribute it to aging alone. Because the thinning is diffuse rather than focal, it can progress significantly before it becomes obvious to others. Women often notice it first as a wider part, a visible scalp under bright light, or a thinner ponytail rather than a distinct bald area.